98%
921
2 minutes
20
Background: Diabetic retinopathy (DR) is the most prevalent microvascular complication of diabetes. Panretinal photocoagulation (PRP) is the established treatment for mitigating severe visual impairment resulting from proliferative DR.
Objective: This study aims to investigate the impact of PRP on the macular region in patients with DR, utilizing optical coherence tomography (OCT) for assessment.
Design: An experimental study was meticulously designed, implementing PRP as the primary intervention.
Setting: The investigation was conducted within the Department of Ophthalmology at the Affiliated Huaian No.1 People's Hospital, Huai'an, Jiangsu, China.
Participants: A total of 120 participants diagnosed with DR and undergoing treatment at our hospital were enrolled in the study.
Interventions: The participants were randomly assigned to either the control group (CG, n = 60) or the study group (SG, n = 60). The CG received conventional drug treatment involving oral iodized lecithin, while the SG received PRP. OCT was employed to monitor changes in macular fovea volume and macular retinal thickness.
Primary Outcome Measures: Evaluation criteria encompassed clinical efficacy, macular fovea volume, macular retinal thickness, IL-6 and VEGF levels, incidence of adverse reactions, and quality of life in both groups.
Results: The study resulted in a higher total effective rate in the SG (96.67%) compared to the CG (80.00%) (χ2 = 8.09, P < .05). Post-treatment, reductions were observed in macular fovea volume and macular retinal thickness, with significantly lower SG values than CG values (P < .05). Both serum IL-6 and VEGF levels exhibited reductions in both groups after treatment, with the SG displaying a more significant decrease compared to the CG (P < .05). The occurrence of adverse reactions significantly decreased in the SG relative to the CG (P < .05). Quality of life scores for the SG was notably elevated compared to the CG (P < .05).
Conclusions: PRP emerges as a highly valuable approach in the management of DR. It contributes to retinal thickness improvement within the macular region and inflammation reduction, and also enhances therapeutic outcomes, minimizes adverse reactions, and optimizes patients' quality of life. These findings warrant further clinical adoption and widespread promotion.
Download full-text PDF |
Source |
---|
Acta Ophthalmol
September 2025
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Purpose: To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration (nAMD).
Methods: This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti-VEGF therapies at Sahlgrenska University Hospital between February 2024 and February 2025. Data on best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height, fluid status, treatment intervals, time to fluid recurrence and adverse events were collected.
Zhonghua Yan Ke Za Zhi
September 2025
Department of traditional Chinese medicine, Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, China.
To assess the current research status of retinal vein occlusion (RVO) and to explore its research trends and hotspots based on bibliometrics. A bibliometric study was conducted on April 25, 2024, retrieving articles from China National Knowledge Infrastructure (CNKI), Wanfang, and Web of Science Core Collection covering 2014 to 2023. CiteSpace, VOSviewer, and Microsoft Excel were used for visualization and analysis of annual publications, country distribution, author productivity, journals, cited references, and keywords.
View Article and Find Full Text PDFVestn Oftalmol
September 2025
Korolev Samara National Research University, Samara, Russia.
Objective: This study evaluated the outcomes of a 36-month follow-up after treatment with the ELLEX 2RT nanosecond laser.
Material And Methods: The study included 72 patients divided into two groups. Group 1 received 2RT nanosecond laser therapy, while group 2 did not undergo laser treatment.
Ophthalmol Sci
July 2025
Department of Ophthalmology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Objective: To examine whether there is an association between age-related macular degeneration (AMD) and dementia using a large, multi-institutional clinical data.
Design: A retrospective cohort study.
Participants: Patients with AMD, including both neovascular AMD (nvAMD) and non-neovascular AMD (non-nvAMD) types, along with matched controls who had a record of eye examination but no diagnosis of AMD.
Ophthalmol Sci
July 2025
Department of Ophthalmology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
Purpose: This study evaluates retinal volume in the macula and peripheral retina in patients with nonproliferative diabetic retinopathy (NPDR), with and without diabetic macular edema (DME), using widefield swept-source OCT (SS-OCT).
Design: Retrospective observational study.
Participants: A total of 98 eyes were included: 30 from patients with NPDR without DME (DME-), 38 from patients with NPDR with DME (DME+), and 30 from age- and sex-matched healthy controls.